Skip to main content

Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma



Tumor-associated lymphangiogenesis is considered significant in number of solid malignancies. However, its impact on prognosis of intrahepatic cholangiocarcinoma (ICC) after resection remains further confirmation. Herein, we conducted this study to evaluate prognostic impact of tumor-associated lymphangiogenesis in patients with ICC.


Extent of tumor-associated lymphangiogenesis of ICC was evaluated by quantifying microlymphatic vessel density (MLVD) from immunohistochemical staining of a lymphatic endothelial-specific antibody (podoplanin). Clinicopathological characteristics were comprehensively analyzed to identify MLVD-associated factors. The patients were stratified into high and low MLVD groups according to the distinctive correlation between the MLVD and overall survival using the Spearman’s correlation test. Kaplan-Meier estimation was performed to confirm prognostic impact of MLVD in patients with ICC. Univariate and multivariate analyses were performed using the Cox proportional hazard model.


The MLVD between 4 to 12 counts showed inverse proportion to the overall survival (Spearman’s r = − 0.66; 95% confidence interval [CI], − 0.82 to − 0.39; p <  0.0001), which was set as a cut-off for the high MLVD group, whereas the MLVD between 13 to 25 showed no correlation to the overall survival (r = − 0.11; 95% CI, − 0.38 to 0.19; p = 0.4791). The high MLVD group showed more frequent lymph node metastasis (p <  0.001) and were more likely to suffer from recurrence of the tumor compared to the low MLVD group (p <  0.001). The high MLVD was found to be independently associated with reduced overall and recurrence-free survival. The 5-year overall survival of the patients with high MLVD was significantly lower compared to those with low MLVD (0% vs 48%).


Our study reveals that tumor-associated lymphangiogenesis is significantly associated with increased lymphatic metastasis, recurrence of the tumor, and reduced overall survival in patients with ICC, thus providing guidance when estimating postresection prognosis.

Peer Review reports


Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer that accounts for approximately 10 to 15% of all primary liver malignancies [1, 2]. Radical resection of the tumor is the potential curative treatment that prolongs survival outcomes [3]. However, most patients lose the opportunity to undergo radical surgery due to advanced stage or extrahepatic metastasis at the time of diagnosis [4]. Moreover, application of adjuvant therapies, such as chemotherapy and radiotherapy, is yet to be conclusively confirmed whether these provide significantly better survival outcomes [5]. In consideration of increasing number of patients and limited therapeutic strategies, a better understanding of potential risk factors of ICC is essential to seek novel anti-tumor targets and to develop new treatment approaches.

Metastasis of tumor cells is one of the leading causes of mortality in ICC and occurs mainly through lymphatic vessels [6]. In recent years, increasing experimental and clinicopathological studies indicated that lymphatic vessels undergo dynamic changes within the tumor, including tumor-associated lymphangiogenesis, that facilitate metastasis [7]. Specific signaling pathways, such as vascular endothelial growth factor C (VEGF-C) and its cognate receptor VEGF receptor 3 (VEGFR-3) are confirmed to stimulate tumor-associated lymphangiogenesis, as well as lymph node metastasis in experimental tumor models [8,9,10]. Apart from that, lymphangiogenesis was found to be associated with increased frequency of tumor cells in lymphatics and lymph nodes in hilar cholangiocarcinoma [11]. However, information regarding the role of tumor-associated lymphangiogenesis in progression and prognosis of ICC remains poor. In this study, we evaluated impact of tumor-associated lymphangiogenesis in patients with ICC, a highly malignant and aggressive primary liver cancer.


Patients and cancer tissues

A total of 106 patients from Jan 2007 to Jul 2015 who underwent hepatic resection with curative intent for ICC were enrolled into the present study. The patients met the criteria as we described before [12]. Briefly, patients who were pathological confirmed of ICC without distant metastasis were included. The present study was applied by the local ethics committee of Renji Hospital, Shanghai Jiao Tong University. Consents from individual patients were waived due to retrospective nature of the study.

Data collection

All patients were followed up in the outpatient at regular intervals and those with unavailable data were visited by telephone inquiries or dropping-in follow up. The primary endpoint of this study was death of patients, and the second endpoint was recurrence of the tumor. Data of last follow-up investigation and recurrence of the tumor were collected for all patients.

Immunohistochemistry and assessment of micro-lymphatic vessel density

To analyze tumor-associated lymphangiogenesis, micro-lymphatic vessel density (MLVD) was determined by quantitative analysis of podoplanin-positive vessels as we described before [12]. Four-micrometer thick tissue sections were collected and incubated with the monoclonal antibodies against podoplanin (rabbit monoclonal, 1:200; Abcam).The lymphatic vessels were counted in three most vascularized fields in non-consecutive sections in a block of tissue and were recorded as total number per unit area. The MLVD count of 4 to 12 vessels composed the low MLVD group according to the statistically greatest inverse proportion to the overall survival in accordance with the mean MLVD (12.59 vessels), whereas the others (≥13 vessels) were subjected to the high MLVD group.

Statistical analysis

The correlation between MLVD category and the clinicopathologic factors were evaluated using the chi-square test. The cut-off value for the MLVD was set by satisfying both the greatest range-dependent correlation with the overall survival and the mean MLVD value. Survival curves were estimated using the Kaplan–Meier method. For identification of independent prognostic factors, the Cox proportional hazard model was used in the univariate and multivariate analyses. All statistical analyses were performed using the SPSS (version 19.0). OR stands for odds ratio that attempts to quantify the strength of the association between different variables. Statistical significance was defined as p <  0.05.


Clinicopathological characteristics

Of the 106 patients enrolled in the study, all patients had undergone liver resection and none received preoperative adjuvant chemotherapy or radiation therapy. The clinicopathological characteristics of the cohort are described in Table 1. The cut-off range, > 9 ng/ml (≥9.1 ng/ml), for AFP was set according to the hospital’s serum positivity for the AFP, which was also the indicative value for hepatocellular carcinoma in some hospitals [13]. Serum CA19–9 was also stratified according to the cut-off value of abnormal elevation (≥35 U/ml), which is a frequently used cut-off value for ICC in Chinese centers, such as Sun Yat-sen University Cancer Center [14]. 42 patients (39.6%) were infected with hepatitis B virus (HBV) before the operation through laboratory tests. Alpha-fetoprotein (AFP), one of the specific tumor markers for hepatocellular carcinoma, was below the normal level in most patients with ICC (n = 78, 73.6%), while CA19–9 was above the cut-off value in majority of patients (n = 73, 68.9%) included in the study. During the operation, number of patients with largest tumor diameter over than 50 mm and multiple tumors nodes was 61 (57.5%) and 17 (16.0%), respectively. Presence of vascular invasion, lymph node metastasis and perineural sheath infiltration, which represented tumor progression, were found in 28, 48, 14 patients, respectively. The median follow-up of total patients was 22.1 months (maximum, 118 months). Tumor recurrence occurred in 72 patients by the end of follow-up.

Table 1 Clinicopathological characteristics of 106 patients with ICC enrolled in the study

Tumor-associated lymphangiogenesis in ICC

Podoplanin-positive lymphatic vessels were detected within the tumors exhibiting both open and collapsed lumina in 106 ICC samples (Fig. 1a-d). In the Spearman’s correlation test for range-dependent MLVD and survival, the greatest p value summary (****; p <  0.0001) was initially identified in a range of 4 to 12 (r = − 0.6589; 95% confidence interval [CI], − 0.8229 to − 0.3936), whereas the range 13 to 25 showed no significant correlation (r = − 0.1058; 95% CI, − 0.3814 to 0.1871; p = 0.4791; Fig. 2 and Table 2). In addition, the calculated MLVD was 12.59 ± 6.10 lymphatic vessels (range, 4 to 25 vessels). Therefore, the impact of the tumor-associated lymphangiogenesis on outcomes and prognosis, patients were divided into the high (> 12 vessels) and low (≤12 vessels) MLVD groups.

Fig. 1

Immunohistochemical staining of podoplanin for evaluation of tumor-associated lymphangiogenesis in ICC. Podoplanin-positive lymphatic vessels exhibited both open and collapsed lumen, respectively (panel a, b; scale bar = 100 μm). Representative tissue sections for high (c) and low (d) MLVD (scale bar = 200 μm)

Fig. 2

Spearman’s correlation test between MLVD and the overall survival. Spearman’s correlation test indicated that the range 4 to 12 MLVDs is a distinctive range with significant inverse proportion to the overall survival (P <  0.0001). However, the range 13 to 25 showed no significant proportion to the overall survival (P = 0.4791), indicating that all patients involved in this range obtained unfavorable prognosis regardless increase of the MLVD. Patients censored before 5 years of follow-up investigation were not included

Table 2 Spearman’s correlation test for stratification of prognostic subtypes according to the MLVD

Correlation between MLVD and clinicopathological characteristics in ICC

To determine the correlation between the degree of tumor-associated lymphangiogenesis and clinicopathological characteristics, we performed a further statistical analysis. The results of clinicopathological analysis are described in Table 3. Patients’ gender and preoperative tumor markers of AFP & CA19–9 were not significantly different between patients with “high MLVD” or “low MLVD”. In contrast, patients with “low MLVD” were more likely to be infected with HBV preoperatively (29 out of 56 vs. 13 out of 50; p = 0.007). In addition, tumors with “high MLVD” showed more frequently lymph node metastasis (32 out of 50 vs. 16 out of 56; p <  0.001) and higher level of TNM stage (40 out of 50 vs. 18 out of 56; p <  0.001) compared with “low MLVD” tumors. Moreover, patients with “high MLVD” developed tumor recurrence more frequently than patients with “low MLVD” (49 out of 50 vs. 23 out of 56; p <  0.001). Other clinicopathological parameters, including tumor size, distribution, number of tumor nodes, vascular invasion, histological differentiation and perineural sheath infiltration were not significantly different between both groups. Further, the MLVD value between patients with different TNM stages was compared as shown in Table 4. It showed that patients with higher level of TNM stage revealed significantly higher MLVD value compared with lower level of TNM stage (15.19 ± 5.70 vs. 9.46 ± 5.05, p <  0.001).

Table 3 Association between micro-lymphatic vessel density (MLVD) and clinicopathological characteristics of the patients with ICC
Table 4 Relationship between micro-lymphatic vessel density (MLVD) and TNM stage in patients with ICC

Analysis of prognostic factors for overall and recurrence-free survival in ICC

We further investigated specific clinicopathological variables predicting overall and recurrence-free survival after hepatic resection of ICC. The results of the univariate and multivariate analysis for overall and recurrence-free survival were described in Tables 5, 6, 7 and 8. In the univariate analysis for overall survival, MLVD, lymph node metastasis, and TNM stage were found to be significantly associated with overall survival (p <  0.001, p = 0.003, p <  0.001, and p <  0.001, respectively). In the multivariate analysis, MLVD (p <  0.001) and tumor size (p = 0.021) were determined as independent prognostic factors for overall survival after hepatic resection of ICC. For recurrence-free survival, MLVD was also identified as an independent risk factor through univariate and multivariate analysis (p <  0.001 and p <  0.001, respectively). In addition, though preoperative HBV infection, tumor size, number of tumor nodes, lymph node metastasis and TNM stage were also associated with recurrence-free survival in the univariate analysis (p = 0.009, p = 0.004, p = 0.049, p <  0.001 and p <  0.001, respectively), only tumor size (p = 0.010) revealed independent prognostic significance for recurrence-free survival.

Table 5 Univariate analysis of prognostic factors for overall survival in ICC
Table 6 Multivariate analysis of prognostic factors for overall survival in ICC
Table 7 Univariate analysis of prognostic factors for recurrence-free survival in ICC
Table 8 Multivariate analysis of prognostic factors for recurrence-free survival in ICC

Impact of MLVD on overall and recurrence-free survival in ICC

Since the abundance of MLVD revealed independent prognostic significance for both overall and recurrence-free survival, we further analyzed the influence of MLVD on survival through Kaplan-Meier method. The 1-, 3-, and 5-year survival of patients with “low MLVD” (n = 56) was 76.8, 66.8 and 48%, respectively. In contrast, the “high MLVD” group (n = 50) displayed 1-, 3-, and 5-year survival of only 20, 0 and 0%, respectively, (p <  0.001), which was much worse than the “low MLVD” group (Fig. 3a). For recurrence-free survival (Fig. 3b), the 1-, 3-, and 5-year survival patients of “low MLVD” was 64.3, 53.8 and 50.4%, respectively, as compared with 4.0, 2.0 and 2.0%, respectively, in patients with “high MLVD” (p <  0.001).

Fig. 3

Impact of different level of tumor-associated lymphangiogenesis and tumor size on overall and recurrence-free survival. (a) The overall survival of the high MLVD group (n = 50) was significantly worse than the low MLVD group (n = 56; p < 0.001). (b) The recurrence-free survival of the high MLVD (n = 50) was also significantly unfavorable than the low MLVD group (n = 56; p < 0.001). (c) Overall survival according to tumor size category revealed that patients with tumors ≥50 mm (n = 61) had worse outcomes than those with < 50 mm (n = 45; p = 0.0017). (d) Patients with tumors ≥50 mm (n = 61) also had much worse recurrence-free survival compared with those with < 50 mm (n = 45; p = 0.0018)

In addition to the abundance of MLVD, tumor size is also one of the risk factors for survival of patients with ICC based on the univariate and multivariate analysis. The 1-, 3-, and 5-year survival of patients with tumors< 50 mm (n = 45) was 66.7, 54.1 and 44%, respectively, as compared with 37.7, 24.9 and 14.8%, respectively, in patients with tumors≥50 mm (n = 61; p <  0.01; Fig. 3c). Furthermore, the recurrence-free survival of patients with tumors≥50 mm was also significantly inferior to patients with tumors< 50 mm, with 1-, 3-, and 5-year survival of 23.0, 19.2, and 16.0%, in contrast to 53.3, 42.9 and 42.9%, respectively (p <  0.01; Fig. 3d).


ICC is a highly malignant neoplasm with a dismal prognosis due to insufficient evident symptoms at the early stage [15]. Up to date, radical hepatic resection remains the only ideal curative treatment for ICC. However, only a minority of patients with ICC are candidates for radical surgical approaches, with a median survival of 6.3 to 16 months [16]. Lack of appropriate medical approaches for ICC calls for further studies on its clinical and biological characteristics. Frequent lymph node metastasis is one of the major hallmarks of ICC that has been identified as a significant prognostic predictor [17, 18], while tumor-associated lymphangiogenesis in prognosis of ICC remains further confirmation.

In the present study, quantitative analysis of MLVD was performed by counting lymphatic vessels stained with podoplanin. Previously, studies of lymphatic vessels and dissemination have been limited due to lack of specific lymphatic markers. Vascular endothelial growth factor receptor-3 (VEGFR-3) was formerly considered as a marker for lymphangiogenesis. However, VEGFR-3 has also been shown to be expressed in blood vessel endothelium and cancer cells [19, 20]. In recent years, some specific markers, including LYVE-1 and podoplanin, have been identified. However, LYVE-1 has also been found to express on the endothelium of blood vessels [21]. In contrast, podoplanin is expressed specifically in lymphatic endothelium and does not exist in blood vasculature [22]. Therefore, podoplanin was chosen to evaluate tumor-associated lymphangiogenesis in the ICC specimens. Moreover, although not described in the present study, lymphatic vessels in adjacent healthy tissues were also evaluated, which ranged from 0 to 5. These vessels seem to play normal biological roles in the propulsion of the lymph circulation considering its no association with metastasis and prognosis of ICC. In addition, high expression of tumor-associated lymphangiogenesis was found to be closely associated with lymph node metastasis and recurrence, suggesting that tumor cells of ICC are likely to migrate along tumor-associated lymphatic vessels into lymph nodes, thus facilitating recurrence of the tumor that leads to poor prognosis. These findings are in line with several previous studies that reported association between lymphatic vessels and lymph node metastasis in mass-forming tumors [23,24,25].

In addition, it is noteworthy that patients with low expression of MLVD seemed to be more likely to be infected with HBV preoperatively (p = 0.007), which was identified as a prognostic factor for recurrence-free survival (p = 0.009). HBV infection has been considered associated with an increasing incidence of ICC in East Asia, where HBV is endemic [26, 27]. However, several studies found that HBV infection may be a favorable factor in patients with ICC. Zhou et al. [28] suggested that the survival of HBV-associated ICC patients was better due to inhibited tumor invasiveness. Wu et al. [29] regarded HBV infection as a favorable factor because of early detection of the unexpected tumor during chronic liver disease follow-up. On the contrary, Ahn et al. [30] reported that 37 HBV-positive and 255 HBV-negative ICC patients showed no significant difference in their outcomes. Since the distribution of HBV infection in ICC was found to vary worldwide, the different results may be attributed to patients enrolled from various regions and different stages of tumor upon diagnosis. Thus, our results require validations in populations from different regions.

Recently, prophylactic lymph node dissection has been considered as a benign factor that might improve the prognosis of the patient with ICC [31]. A study from Japan rendered that the wide dissection, including the regional and para-aortic lymph nodes, along with hemihepatectomy was found to be curative in the first 5-year survivor with periductal-infiltrating ICC [32]. Since tumor-associated lymphangiogenesis is an important independent prognostic factor that deteriorates survival by promoting lymph node metastasis, intraoperative biopsy to evaluate extent of tumor-associated lymphangiogenesis may support decision for performance lymphadenectomy.

Moreover, tumor-associated lymphangiogenesis may serve as one of the novel therapeutic targets of ICC, of which the VEGF-C/VEGF-D-VEGFR3 axis is considered a major driver of tumor-associated lymphangiogenesis [33]. In addition, other growth factors and signaling pathways are also involved in lymphangiogenesis. VEGF-A was found to promote lymphangiogenesis and lymph node metastasis in a mouse fibrosarcoma xenograft model [34]. Platelet-derived growth factor B also induced tumor lymphangiogenesis and promoted lymph node metastasis in mice, but this could not be prevented using a VEGFR3-targeted antibody [35]. While, transforming growth factor-β (TGF-β) has been reported to be a negative regulator of lymphangiogenesis in cancer. Inhibition of endogenous TGF-β signaling in mouse xenograft models of pancreatic adenocarcinoma induced lymphangiogenesis [36]. Based on these findings, various tyrosine kinase inhibitors targeting VEGF, EGRF or FGF receptors such as sorafenib, sunitinib, regorafenib, etc. are under clinical trials for different types of tumor [37,38,39]. Since clinical trials and reports about antitumor therapy targeting lymphangiogenesis in ICC are still rare, the results of our study may provide a novel view of treatment for ICC.

This study provides a great deal of information about the critical influence of tumor-associated lymphangiogenesis on prognosis of hepatic resected patients with ICC. However, there are a few underlying limitations that remain to be confirmed. Firstly, limited number of patients may cause bias of the results, which could be improved by additional large-scaled studies. Secondly, the involved patients were local malignancies within the liver, patients with advanced and metastatic tumors may result in different outcomes. Lastly, all the involved patients were from Eastern countries, further confirmations by patients from other regions are needed.


High extent of tumor-associated lymphangiogenesis is significantly associated with lymph node metastasis and recurrence of the tumor in ICC. MLVD, a indicative factor for the extent of tumor-associated lymphangiogenesis, was found to be an independent prognostic factor for overall and recurrence-free survival in patients with ICC after resection. Evaluation of tumor-associated lymphangiogenesis by intraoperative biopsy seems promising to possess a great potential to improve survival outcomes by providing guidance to patient selection who may benefit from lymphadenectomy. We call for future large-scale prospective trials to verify our results for general application in real-world clinical medicine.





Carbohydrate antigen 19–9


Hepatitis B virus


Intrahepatic cholangiocarcinoma


Micro-lymphatic vessel density


  1. 1.

    Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–79.

    Article  Google Scholar 

  2. 2.

    Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139:1534–45.

    CAS  Article  Google Scholar 

  3. 3.

    Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215–29.

    CAS  Article  Google Scholar 

  4. 4.

    Yuan L, Luo X, Lu X, Huang B, Cai Q. Liver resection for intrahepatic cholangiocarcinoma in AJCC stage IV: an evaluation of the survival benefit and prognostic accuracy of current AJCC staging system on N and M classification. Oncol Rep. 2016;36:2663–72.

    CAS  Article  Google Scholar 

  5. 5.

    Song S, Kim K, Chie EK, Kim S, Park HJ, Yi NJ, Suh KS, Ha SW. Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy. Clin Transl Oncol. 2015;17:825–9.

    CAS  Article  Google Scholar 

  6. 6.

    Aishima S, Nishihara Y, Iquchi T, Taquchi K, Taketomi A, Maehara Y, Tsuneyoshi M. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol. 2008;21:256–64.

    CAS  Article  Google Scholar 

  7. 7.

    Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodeling in cancer. Nat Rev Cancer. 2014;14:159–72.

    CAS  Article  Google Scholar 

  8. 8.

    Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192–8.

    CAS  Article  Google Scholar 

  9. 9.

    Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, et al. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014;5:4944.

    CAS  Article  Google Scholar 

  10. 10.

    Wakisaka N, Hirota K, Kondo S, Sawada-Kitamura S, Endo K, Murono S, Yoshizaki T. Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma. Oral Oncol. 2012;48:703–8.

    CAS  Article  Google Scholar 

  11. 11.

    Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, Wiedenmann B, Neuhaus P, Jonas S. Tumor-associated lymphangiogenesis correlates with lymphnode metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:791–9.

    Article  Google Scholar 

  12. 12.

    Sha M, Jeong S, Chen XS, Tong Y, Cao J, et al. Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis. Int J Biol Sci. 2018;14:1333–42.

    Article  Google Scholar 

  13. 13.

    Chiang HH, Lee CM, Hu TH, Hung CH, Wang JH, et al. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int. 2018;38:1997–2005.

    CAS  Article  Google Scholar 

  14. 14.

    He C, Zhang Y, Song Y, Wang J, Xing K, Lin X, Li S. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer. 2018;9:3117–28.

    Article  Google Scholar 

  15. 15.

    Bridgewater J, Galle PR, Khan SA, Llovet JM, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.

    Article  Google Scholar 

  16. 16.

    Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing incidence. J Am Coll Surg. 2008;207:594–603.

    Article  Google Scholar 

  17. 17.

    Amini N, Eiaz A, Spolverato G, Maithel SK, Kim Y, Pawlik TM. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014;18:2136–48.

    Article  Google Scholar 

  18. 18.

    De Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;10:3140–5.

    Article  Google Scholar 

  19. 19.

    Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381–90.

    CAS  Article  Google Scholar 

  20. 20.

    Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, Vassy R, Czernichow S, Letoumelin P, Breau JL, Bernaudin JF, Kraemer M. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer. 2007;58:205–13.

    Article  Google Scholar 

  21. 21.

    Gordon EJ, Gale NW, Harvey NL. Expression of the hyaluronan receptor LYVE-1 is not restricted to the lymphatic vasculature: LYVE-1 is also expressed on embryonic blood vessels. Dev Dyn. 2008;237:1901–9.

    CAS  Article  Google Scholar 

  22. 22.

    Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries:podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385–394.

  23. 23.

    Du LC, Chen XC, Wang D, Wen YJ, Wang CT, Wang XM, Kan B, Wei YQ, Zhao X. VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma. Reprod Bio Endocrinol. 2014;12:14.

    Article  Google Scholar 

  24. 24.

    Watanabe M, Tanaka H, Ohira M, Yoshii M, et al. Intranodal lymphangiogenesis precedes development of lymph node metastasis and accelerates progression of gastric cancer. J Gastrointest Surg. 2014;18:481–90.

    Article  Google Scholar 

  25. 25.

    Ueda A, Matsumoto T, Komuro Y. Lymphangiogenesis is a predictor of nodal metastasis in extramammary Paget's disease. Histopathology. 2011;58:870–4.

    Article  Google Scholar 

  26. 26.

    Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, Kwon S, Lee SK, Seo DW, Kim MH, Suh DJ. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008;103:1716–20.

    Article  Google Scholar 

  27. 27.

    Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, Wang YL, Li DQ. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol. 2008;14:632–5.

    Article  Google Scholar 

  28. 28.

    Zhou HB, Wang H, Li YQ, et al. Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol. 2011;17:1292–303.

    Article  Google Scholar 

  29. 29.

    Wu ZF, Yang N, Li DY, Zhang HB, Yang GS. Characteristics of intrahepatic cholangiocarcinoma in patients with hepatitis B virus infection: clinicopathologic study of resected tumours. J Viral Hepat. 2013;20:306–10.

    CAS  Article  Google Scholar 

  30. 30.

    Ahn CS, Hwang S, Lee YJ, Kim KH, Moon DB, Ha TY, Song GW, Lee SG. Prognostic impact of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma. ANZ J Surg. 2018;88:212–7.

    Article  Google Scholar 

  31. 31.

    Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, Chung JB. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16:3048–56.

    Article  Google Scholar 

  32. 32.

    Murakami Y, Yokoyama T, Takesue Y, Hiyama E, Yokoyama Y, Kanehiro T, Uemura K, Matsuura Y. Long-term survival of peripheral intrahepatic cholangiocarcinoma with metastasis to the Para-aortic lymph nodes. Surgery. 2000;127:105–6.

    CAS  Article  Google Scholar 

  33. 33.

    Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 2010;140:460–76.

    CAS  Article  Google Scholar 

  34. 34.

    Bjorndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, Wu L, Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 2005;65:9261–8.

    Article  Google Scholar 

  35. 35.

    Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 2004;6:333–45.

    CAS  Article  Google Scholar 

  36. 36.

    Oka M, Iwata C, Suzuki HI, Kiyono K, Morishita Y, et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood. 2008;111:4571–9.

    CAS  Article  Google Scholar 

  37. 37.

    Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559–66.

    CAS  Article  Google Scholar 

  38. 38.

    Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008–16.

    CAS  Article  Google Scholar 

  39. 39.

    Li J, Qin S, Xu R, Yau TC, Ma B, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29.

    CAS  Article  Google Scholar 

Download references


Not applicable.


This work was supported by the National Natural Science Foundation of China (81472234, 81670598 to Q Xia,), and the Shanghai Health Bureau Key Joint Efforts Foundation (2013ZYJB001) to Q Xia. None of the funding bodies had any part in the design of the study and collection, analysis and interpretation of data, or in writing the manuscript.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Author information




MS and SJ conducted the present study. MS drafted the manuscript. MS, SJ, XW, YT, JC, HYS, LX, NX and ZFX collected clinical data. MS and XW performed the statistical analyses. MS, SJ, XW, YT, JC, HYS, LX, NX, ZFX and JJZ participated in the study design and concept. XNK and QX revised the manuscript critically for intellectual content. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Qiang Xia.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the local ethics committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University. The requirement for informed consent was waived given the retrospective nature of the data, that was applied by the ethics committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sha, M., Jeong, S., Wang, X. et al. Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma. BMC Cancer 19, 208 (2019).

Download citation


  • Tumor-associated lymphangiogenesis
  • Intrahepatic cholangiocarcinoma
  • Prognosis
  • Overall survival
  • Recurrence-free survival